Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts - 09/12/21
Key words : atopic dermatitis, autoimmune diseases, biologics, COVID-19, IL-4A, IL-12/22, IL-17A, psoriasis, systemic immunosuppression, systemic lupus erythematosus, TNF
Drs Pahalyants and Murphy are cofirst authors. |
|
IRB approval status: Approved by the institutional review boards of Mass General Brigham (Protocol 2020P001191) and Massachusetts Department of Public Health (Protocol 1606024-2). |
|
Funding sources: None. |
Vol 86 - N° 1
P. 252-255 - janvier 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.